Abstract
Most current anticancer therapies induce tumor cell death through apoptosis where its specific involved pathways are poorly understood. For example, for many DNA-damaging agents, the specific biochemical lesions (DNA adducts) are associated with the induction of apoptosis via the mitochondria death pathway. However, several of these DNA-damaging agents like cisplatin induce apoptosis through plasma membrane disruption, triggering the Fas death receptor pathway. In this review, we focus on the role of early plasma membrane events in cisplatin-induced apoptosis. Special attention is given to changes in plasma membrane fluidity, inhibition of NHE1 exchanger, activation of acid sphingomyelinase and their consequences on the Fas death pathway in response to cisplatin.
Keywords: membrane fluidity, membrane lipid rafts, acid sphingomyelinase, Fas death receptor, Na+/H+ exchanger 1 (NHE1), DNA adducts
Current Medicinal Chemistry
Title: Cisplatin Cytotoxicity: DNA and Plasma Membrane Targets
Volume: 15 Issue: 26
Author(s): Amelie Rebillard, Dominique Lagadic-Gossmann and Marie-Therese Dimanche-Boitrel
Affiliation:
Keywords: membrane fluidity, membrane lipid rafts, acid sphingomyelinase, Fas death receptor, Na+/H+ exchanger 1 (NHE1), DNA adducts
Abstract: Most current anticancer therapies induce tumor cell death through apoptosis where its specific involved pathways are poorly understood. For example, for many DNA-damaging agents, the specific biochemical lesions (DNA adducts) are associated with the induction of apoptosis via the mitochondria death pathway. However, several of these DNA-damaging agents like cisplatin induce apoptosis through plasma membrane disruption, triggering the Fas death receptor pathway. In this review, we focus on the role of early plasma membrane events in cisplatin-induced apoptosis. Special attention is given to changes in plasma membrane fluidity, inhibition of NHE1 exchanger, activation of acid sphingomyelinase and their consequences on the Fas death pathway in response to cisplatin.
Export Options
About this article
Cite this article as:
Rebillard Amelie, Lagadic-Gossmann Dominique and Dimanche-Boitrel Marie-Therese, Cisplatin Cytotoxicity: DNA and Plasma Membrane Targets, Current Medicinal Chemistry 2008; 15 (26) . https://dx.doi.org/10.2174/092986708786242903
DOI https://dx.doi.org/10.2174/092986708786242903 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Q-TOF LC/MS-based Untargeted Metabolomics Approach to Evaluate the Effect of Folate-Conjugated Cyclodextrins on Triple-Negative Breast Cancer Cells
Current Pharmaceutical Analysis 3D QSAR of Aminophenyl Benzamide Derivatives as Histone Deacetylase Inhibitors
Medicinal Chemistry Image Fusion Based on Estimation Theory: Applied to PET/CT for Radiotherapy
Recent Patents on Medical Imaging Targeted Drug Delivery for Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Molecular Based Drug Targets for Idiopathic Pulmonary Fibrosis
Current Respiratory Medicine Reviews From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer
Reviews on Recent Clinical Trials Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer
Current Pharmaceutical Design Design, Synthesis and Studies on Novel Polymeric Prodrugs of Erlotinib for Colon Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Natural Products as PI3K/ Akt Inhibitors: Implications in Preventing Hepatocellular Carcinoma
Current Molecular Pharmacology The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines
Letters in Drug Design & Discovery Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities
Applied Clinical Research, Clinical Trials and Regulatory Affairs Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets World Health Organization Classification of Myelodysplastic Syndromes
Current Pharmaceutical Design Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs
Current Medicinal Chemistry Molecular Targeting of Drug Delivery Systems to Cancer
Current Drug Targets Radionuclide Based Imaging of Prostate Cancer
Current Topics in Medicinal Chemistry Curcumin Therapeutic Modulation of the Wnt Signaling Pathway
Current Pharmaceutical Biotechnology